长春高新(000661) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 2,997,478,589.10, a decrease of 5.66% compared to CNY 3,177,355,203.27 in the same period last year[5] - Net profit attributable to shareholders was CNY 472,704,862.34, down 44.95% from CNY 858,728,236.98 year-on-year[5] - The basic earnings per share decreased to CNY 1.17, a decline of 45.07% compared to CNY 2.13 in the previous year[5] - Total operating revenue decreased to CNY 2,997,478,589.10 from CNY 3,177,355,203.27, representing a decline of approximately 5.65% year-over-year[19] - Total operating costs increased to CNY 2,422,413,505.22 from CNY 2,102,994,280.55, marking an increase of about 15.19% year-over-year[19] - Net profit attributable to the parent company decreased to CNY 472,704,862.34 from CNY 858,728,236.98, a decline of approximately 44.93% year-over-year[20] - Basic earnings per share decreased to CNY 1.17 from CNY 2.13, reflecting a drop of about 45% year-over-year[21] - Total comprehensive income decreased to CNY 468,710,472.39 from CNY 889,346,936.00, a decline of approximately 47.3% year-over-year[21] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 571,068,215.38, representing a 49.72% decrease from CNY 1,135,769,256.97 in the same period last year[5] - The net cash flow from investing activities was -2,697,676,383.92, indicating a significant outflow compared to the previous period's outflow of -659,395,909.82[24] - The net cash flow from financing activities was -75,189,681.00, a decrease from -480,108,431.16 in the prior period, reflecting reduced cash outflows[24] - The total cash and cash equivalents at the end of the period amounted to 3,828,444,255.44, down from 7,535,306,650.71 at the beginning of the period[24] - The cash and cash equivalents net increase for the period was -2,202,162,630.64, compared to -3,747,375.91 in the previous period[24] - Cash paid for debt repayment was 207,984,031.57, significantly lower than 629,301,008.75 in the prior period[24] - The company distributed dividends and interest payments totaling 17,251,796.63, compared to 9,345,037.33 previously[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 31,696,330,314.92, an increase of 2.08% from CNY 31,051,118,040.40 at the end of the previous year[5] - Total current assets decreased from CNY 16,270,250,650.56 to CNY 15,973,804,458.05, a decline of approximately 1.8%[15] - Total liabilities increased from CNY 4,948,673,308.81 to CNY 5,133,838,859.72, an increase of about 3.7%[17] - Total non-current assets increased from CNY 14,780,867,389.84 to CNY 15,722,525,856.87, an increase of approximately 6.4%[16] - Total equity attributable to shareholders increased to CNY 23,472,599,231.87 from CNY 22,999,514,866.29, an increase of approximately 2.05%[18] - Total liabilities and equity increased to CNY 31,696,330,314.92 from CNY 31,051,118,040.40, reflecting an increase of about 2.08%[18] Research and Development - The company continues to accelerate the R&D of key new products, including Class 1 innovative drugs, leading to increased R&D expenditures[10] - Research and development expenses increased to CNY 513,603,621.78 from CNY 421,532,747.26, an increase of about 21.8% year-over-year[20] Other Financial Metrics - The company reported a significant increase in sales personnel, contributing to higher expenses and impacting net profit[10] - Other comprehensive income after tax decreased to CNY -706,693.40 from CNY -2,362,751.60, indicating an improvement in losses[21] - The impact of exchange rate changes on cash and cash equivalents was -364,781.10, a minor change from -12,291.90 in the previous period[24] - The first quarter report was not audited, indicating that the financial data may be subject to further review[25] - The company will implement new accounting standards starting in 2025, which may affect future financial reporting[26]